Navigation Links
Atrium Innovations to Hold 2007 Third Quarter Financial Results Conference Call and Webcast on November 8
Date:10/24/2007

QUEBEC, Oct. 24 /PRNewswire-FirstCall/ - Atrium Innovations Inc. (TSX: ATB) will hold its quarterly conference call and webcast at 10 a.m. Eastern time on November 8, 2007. The call will follow the press release of Atrium's 2007 third quarter results issued earlier the previous day. Participants may access the call by using the following numbers: 416-644-3418, 514-807-8791 or 800-591-7539 or via the Company's website at http://www.atrium-innov.com in the "Investors" section.

A replay of the webcast will also be available on our website http://www.atrium-innov.com in the "Investors" section for a period of 30 days.

About Atrium

Atrium Innovations Inc. is a recognized leading developer, manufacturer and marketer of science-based products for the cosmetics, pharmaceutical, chemical and nutrition industries. The Company focuses primarily on growing segments of the health and personal care markets which are benefiting from the trends towards healthy living and the ageing of the population. Atrium markets a broad portfolio of active ingredients, specialty chemicals and health and nutrition finished products through its highly specialized sales and marketing network in more than 50 countries, primarily in North America, Europe and Asia. Atrium has over 600 employees and operates four manufacturing facilities. Additional information about Atrium is available on its Web site at http://www.atrium-innov.com.

Cautionary Note and Forward-Looking Statements

This press release contains certain forward-looking statements with respect to the Company. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by these forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable, but cautions the reader that these assumptions regarding future events, many of which are beyond its control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect the Company. For additional information with respect to these and other factors, see the Company's quarterly and annual filings with the Canadian securities commissions. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.


'/>"/>
SOURCE Atrium Innovations Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Pilot fund brings capital to Eau Claire area innovations
2. Wisconsin state agencies commended for digital innovations
3. Oshkoshs Pierce Security Vehicle Ranked in top 100 Technological Innovations for 2003
4. Visions: Broderick says Wisconsin should be in top third in venture capital
5. Third Wave files countersuit vs. Digene in patent case
6. Third Wave reports net loss of $18.9M for 2006
7. Stratagene to pay Third Wave $10.75M in patent case
8. Third Wave responds to Digene patent lawsuit
9. Third Wave seeks approval of Cystic Fibrosis test
10. Third Wave Technologies to raise $14.9M through private debt
11. Venture capital above $6B for third straight quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... VA (PRWEB) , ... March 29, 2017 , ... ... wearable patch comprising multiple separable adhesive layers, as issued by the U.S. Patent ... layers as it applies to combining electronics and health monitoring. This invention will ...
(Date:3/29/2017)... OF PRUSSIA, Pa. , March 29, 2017 /PRNewswire/ ... to care, which is why CSL Behring awards Local ... work of rare disease patient groups. These groups tackle ... voices are heard on Capitol Hill and in statehouses ... funding cycle, the community-based grant was awarded to New ...
(Date:3/29/2017)... , March 29, 2017 QIAGEN N.V. (NASDAQ: ... announced the U.S. launch of its ipsogen ® JAK2 RGQ ... Food and Drug Administration as a qualitative in vitro diagnostic test for the ... blood.* ... is processed on QIAGEN,s Rotor-Gene ® Q MDx system, which is a ...
(Date:3/29/2017)... year,s petition to the White House signed by 120,000 ... generate awareness on the importance of new organic medicines and nutritional ... place. ... this month Health Advance (OTC PINK: HADV ), ... announced its endeavors on this generally recognized as safe ...
Breaking Biology Technology:
(Date:2/27/2017)... Feb. 27, 2017   Strategic Cyber Ventures , ... has led a $3.5 million investment in  Polarity , ... Cyber Ventures is DC based and is led by ... Thomas . Ron Gula , also a longtime ... participated in this series A round of funding. This ...
(Date:2/22/2017)... LONDON , Feb. 22, 2017 ... by 2021, ABI Research identifies four technologies that ... solutions to secure significant share in the changing ... payments, and passive authentication.   "Companies ... it comes to security," says Dimitrios Pavlakis ...
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a ... announced that it has received Laboratory Accreditation from ... Accreditation is presented to laboratories that meet stringent ... demonstrate scientifically rigorous processes. "Genos is ... in laboratory practices. We,re honored to be receiving ...
Breaking Biology News(10 mins):